

ASA404 prostate cancer phase II data
15 Aug 2008

The logo for ANTISOMA features the word "ANTISOMA" in a bold, dark blue, sans-serif font. The text is centered horizontally and is overlaid on a stylized orange sunburst graphic. The sunburst consists of multiple sharp, triangular rays of varying lengths radiating from a central point behind the letters. The rays are a vibrant orange color. The entire logo is set against a white background.

ANTISOMA

Except for the historical information presented, certain matters discussed in this presentation are forward looking statements that are subject to a number of risks and uncertainties that could cause actual results to differ materially from results, performance or achievements expressed or implied by such statements. These risks and uncertainties may be associated with product discovery and development, including statements regarding the company's clinical development programs, the expected timing of clinical trials and regulatory filings. Such statements are based on management's current expectations, but actual results may differ materially

This presentation is only being made available or communicated to persons whom Antisoma is legally authorized to make the presentation. Persons who do not fall within this category should leave the presentation. This presentation is not for distribution in any other country.

The presentation and this document do not constitute an offer or invitation for the sale and purchase of any securities or of any of the assets, undertakings or entities described herein.



Prostate cancer trial evaluated ASA404 with Taxotere (docetaxel)

- ★ 74 patient randomized phase II trial
- ★ Patients with hormone-refractory metastatic prostate cancer
 - First-line treatment
- ★ 1200 mg/m² ASA404 + Taxotere vs Taxotere alone


Survival comparisons for ASA404 vs control

- ★ Survival hazard ratio 0.8 (CI 0.46—1.39)
 - 20% reduction in risk of death in ASA404 group
- ★ Median survival 17.0 vs 17.2 months
- ★ Two-year survival 33% vs 22%

Other comparisons for ASA404 vs control

- ★ PSA response rate 59% vs 37%
- ★ RECIST response rate 23% vs 9%
- ★ Time to disease progression 7.3 vs 6.9 months
- ★ Addition of ASA404 to Taxotere generally well tolerated

*Individual patients' PSA changes after treatment
(orange = ASA404; grey = control)*



- ★ Evidence of ASA404 activity in prostate cancer
- ★ Next steps in prostate cancer to be decided by Novartis
- ★ Novartis conducting wider analysis of development opportunities
 - Thorough lung phase III programme underway
 - Plans for other indications being considered